Jon Congleton was appointed to Immunic's board of directors effective March 27, 2026, as a Class II director12
Congleton brings nearly 40 years of biopharmaceutical experience with focus on central nervous system therapeutics and multiple sclerosis treatments1
He was part of the team that launched Copaxone in the United States for Teva Pharmaceuticals and later led U.S. operations when it became the top-prescribed MS therapy1
Congleton currently serves as CEO and board member of Mineralys Therapeutics, Inc.1
He previously held CEO positions at Impel NeuroPharma, Inc. and Nivalis Therapeutics, Inc.1
Congleton was appointed as Chair of the Compensation Committee2
Immunic's board size increased from eight to nine directors with his appointment2
Congleton received stock options to purchase 500,000 shares vesting monthly over three years2
Immunic's lead program, vidofludimus calcium (IMU-838), is in phase 3 clinical trials for relapsing multiple sclerosis with top-line data expected by end of 20261
Sources:
1. https://www.investing.com/news/company-news/immunic-appoints-jon-congleton-to-board-of-directors-93CH-4589798
2. https://www.stocktitan.net/sec-filings/IMUX/8-k-immunic-inc-reports-material-event-3180e718fd4f.html